With Pipeline of Syndromic Tests, Qorvo Eyes Emergence as More Than a COVID Company
Article By Greg Cima / April 25, 2023
Qorvo Biotechnologies said it is closing in on the launch of its point-of-care COVID-19 and influenza test as the firm works to expand its menu beyond COVID-19 and into syndromic panels and cardiac disease tests.
News
ProjectMedtech Podcast | Strategic Transactions in MedTech: Insights & Advice
Recent podcast conversation featuring Stanislav Glezer, Managing Director at Outcome Capital, on the ProjectMedtech Podcast, hosted by Duane Mancini.
Read MoreResources
Outcome Capital Life Science Market Pulse
Outcome Capital Life Science Market Pulse February 2026 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2026. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Outcome Capital and Outcome Life Sciences are affiliates of Outcome Holdings, LLC
Business Continuity Plan | Privacy Policy | Regulation Best Interest
